ImageneBio (IMA)

The company’s lead programme is IMG-007, a monoclonal antibody designed to target OX40, a receptor found on activated T cells. The OX40/OX40L pathway is involved in sustaining immune responses, and blocking it is being explored as a way to reduce harmful inflammation in diseases where the immune system attacks healthy tissue or becomes chronically overactive. IMG-007 is described as a non-depleting anti-OX40 antibody, meaning it is intended to interfere with receptor signalling without broadly eliminating the T cells that express the receptor.

ImageneBio is evaluating IMG-007 as a potential treatment platform across multiple autoimmune and inflammatory indications. This approach reflects a common strategy in biotechnology: developing a mechanism that may be relevant to several related disorders, then expanding into additional indications if early clinical and safety data support further development.

The company operates as a single business segment, centred on biopharmaceutical research and development. For investors, ImageneBio represents exposure to a specialised immunology pipeline, with the typical opportunities and risks of clinical-stage drug development, including lengthy trial timelines, uncertain regulatory outcomes, and significant capital requirements.